DuraGraft® is a first in class Endothelial Damage Inhibitor (EDI) intended for the flushing, storage and preservation of vascular conduits. DuraGraft may improve endothelial function and structure, thereby reducing graft failure rates and improving clinical outcomes. DuraGraft has been shown to reduce major cardiac events five years post-CABG, including myocardial infarction, repeat revascularization, and MACE. Learn more about DuraGraft.

Based on US Retrospective Study - more than 2000 CABG Patients

48%

Reduction in
Myocardial Infarction
p=0.0001

53%

Reduction in
Repeat Revascularization
p=0.02

*Manuscript in preparation

18%

Reduction in
MACE
p=0.02